[1] 陶鑫良.谈谈药品新用途专利问题[N/OL].（2020-02-12）[2021-04-25].http://ip.people.com.cn/n1/2020/0212/c179663-31583518.html.[2] 尹新天.中国专利法详解[M].北京:知识产权出版社,2011.[3] 魏永燕.中欧专利实践中关于医药用途发明专利新颖性的比较分析[C]//2014年中华全国专利代理人协会年会第五届知识产权论坛论文集（第一部分）,2014:233-240.[4] 中华人民共和国国家知识产权局.专利审查指南2010(修订版)[M].北京:知识产权出版社,2017.[5] 张维.药物产品专利与用途专利有啥区别[N].法制日报,2020-02-07(4).[6] FORSBERG J.A skinny label:the intersection of EU competition law and patent law, and the abuse of dominance by the enforcement of second medical use patents[D/OL].(2016-02-09)[2021-04-25].http://lup.lub.lu.se/luur/download?func=downloadFile&recordOId=8507627&fileOId=8521854.[7] COHEN J,WILSON A,FADEN L.Off-label use reimbursement[J].Food and Drug Law Journal,2009,64(2):391-403.[8] 肖鹏,冯铻战.制药用途专利在欧洲的终结及对我国的影响和启示[J].知识产权,2010,20(3):38-45.[9] 新华社.全国人民代表大会常务委员会关于修改《中华人民共和国专利法》的决定[N/OL].(2020-10-18)[2021-04-25].https://www.sohu.com/a/425730148_699502.[10] EPO.Notice from the European Patent Office dated 20 September 2010 concerning the non-acceptance of Swiss-type claims for second or further medical use following decision G 2/08 of the Enlarged Board of Appeal [R/OL].(2016-02-08)[2020-04-25].https://www.epo.org/law-practice/legal-texts/official-journal/2016/etc/se4/p258.html.[11] 国家知识产权局.专利审查指南2010(修订版) [M].北京:知识产权出版社,2017.[12] CAMILLA BALLENY.Skinny labels and infringement[R/OL].(2019-05-19)[2021-04-25].https://www.carpmaels.com/obiter-dicta-skinny-labels-and-infringement/.[13] DUNCAN G,WILLOUGHBY R.UK Supreme Court decides on pregabalin second medical use patent[J].Pharmaceutical Patent Analyst,2019,8(3):81-85.[14] Glaxosmithkline LLC v.teva pharmaceuticals USA,inc.United States court of appeals of the federal circuit,2020 976 F.3d 1347[J].Biotechnology Law Report,2020,39(6):487-502.[15] 吴柯苇.仿制药专利挑战机制解释学分析与进路选择[J].科技进步与对策,2021,38(1):79-86.[16] 姚志明.侵权行为法[M].中国台北：元照出版有限公司, 2014:15-16.[17] 崔国斌.专利法：原理与案例[M].北京:北京大学出版社,2012.[18] 邢维伟,刘姝晶.对诺华和正大天晴关于甲磺酸伊马替尼专利诉讼案的思考[J].中国发明与专利,2015(4):90-93.[19] (古希腊)亚里士多德.政治学[M].北京:商务印书馆,1965.
